{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 27 of 128', '2 Trial identification', 'EudraCT number: 2018-000900-40', 'IND number:', 'NCT number: NCT03683719', 'The clinical trial protocol will be registered in local registries if required by local legislation.', '3 Schematic of trial design', 'Panel 1: Trial design', 'Screening', 'Treatment', 'Follow-up', 'Delgocitinib cream 20 mg/g (b.i.d.)', 'Delgocitinib cream 8 mg/g (b.i.d.)', '250 subjects', '1:1:1:1:1', 'randomisation', 'Delgocitinib cream 3 mg/g (b.i.d.)', 'stratified by region &', 'IGA baseline s\u00e9verity', 'Delgocitinib cream 1 mg/g (b.i.d.)', 'Delgocitinib cream vehicle (b.i.d.)', 'Primary endpoint', 'Visit No.', '1', '2 3 4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '-28d', '-7d 1d', '29d', '57d', '85d', '113d', '127d', '-4w', '-1w Ow', '4w', '8w', '12w', '16w', '18w', 'Time from start of treatment', \"Abbreviations: IGA, Investigator's Global Assessment; b.i.d (bis in die), twice a day; d, day; W, week.\"]['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 28 of 128', '4 Schedule of trial procedures', 'Panel 2: Schedule of trial procedures', 'Screening', 'Treatment period', 'Follow-', 'Primary', 'Unscheduled', 'References', 'End of treatment/', 'up4', 'endpoint', 'visit, if', '(protocol', 'early termination\u00b3', 'visit at', 'applicable6', 'section)', 'Week 16,', 'Visit', '1', '2', '3\u00b2', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', 'if', 'Week', '-4 to -1', '0', '1', '2', '4', '6', '8', '10', '12', '14', '16', '18', 'applicable5', 'Day', '-28 to -7', '1', '4', '8', '15', '29', '43', '57', '71', '85', '99', '113', '127', 'Visit window (days\u00b9', '-', '-', '1', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', 'Trial population and eligibility', 'Informed consent7', 'X', 'Appendix 3B', 'Subject eligibility', 'X', 'X', '8.1,8.2,8.3', 'Trial products and randomisation', 'Randomisation', 'X', '9.3', 'Dispense IMP', 'X', 'X', 'X', 'X', 'X', '(X)', '9.2', 'Instruction on IMP', 'X', '9.2', 'application', 'Application of IMP', 'twice daily', '9.2', 'Treatment compliance', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '9.8.3,9.8.4', 'Return of IMP and', '9.8.3, 10.3,', 'X', 'X', 'X', 'accountability8', '10.4', 'Concomitant medication,', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'concurrent procedures9', '(X)', '9.4,9.5,9.6,', '9.7']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 29 of 128', 'Screening', 'Treatment period', 'Follow-', 'Primary', 'Unscheduled', 'References', 'End of treatment/', 'up4', 'endpoint', 'visit, if', '(protocol', 'early termination\u00b3', 'visit at', 'applicable6', 'section)', 'Week 16,', 'Visit', '1', '2', '3\u00b2', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', 'if', 'Week', '-4 to -1', '0', '1', '2', '4', '6', '8', '10', '12', '14', '16', '18', 'applicable5', 'Day', '-28 to -7', '1', '4', '8', '15', '29', '43', '57', '71', '85', '99', '113', '127', 'Visit window (days\u00b9', '-', '-', '1', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', '+3', 'Investigator assessments at screening/baseline only', 'Demographics', 'X', '11.2.1', 'Fitzpatrick skin type', 'X', '11.2.2', 'Medical history10', 'X', '11.2.3', 'Classification of chronic', 'X', '11.2.4', 'hand eczema', 'Height and weight', '11.2.5', 'Determination of the', '11.2.6', 'treatment areas', 'eDiary hand out / training', 'X', '7.1', 'Subject assessment of efficacy - daily', 'eDiary completion: HESD11', 'daily', '11.7.1.1', 'Subject assessment of efficacy and health-related quality of life - during trial visits', 'HEIS', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '11.7.1.2', 'PaGA', 'X', 'X', 'X', '11.7.1.3', 'PGI-C', 'X', '11.7.1.4', 'DLQI', 'X', 'X', '11.7.1.5', 'EQ-5D-5L', 'X', 'X', '11.7.1.6', 'QOLHEQ', 'X', 'X', '11.7.1.7']\n\n###\n\n", "completion": "END"}